REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

REGENXBIO (Nasdaq: RGNX) will present at the 44th Annual J.P.

Rhea-AI Summary

REGENXBIO (Nasdaq: RGNX) will present at the 44th Annual J.P. Morgan Healthcare Conference.

Date & time: Wednesday, January 14, 2026 at 10:30 a.m. PT. Location: Westin St. Francis, San Francisco, CA.

A live webcast will be available in the Investors section of the company's website and an archived replay will be posted for approximately 30 days after the presentation.

Argus Dec 18 session

+2.58% close to close Open Argus

Details

News Market Reaction – RGNX

On Dec 18, the day this news came out, RGNX closed 2.58% above the previous close.

Data tracked by StockTitan Argus for the Dec 18 session.

Market Context

This announcement details REGENXBIO’s planned presentation at the 44th Annual J.P. Morgan Healthcare...

Analysis

This announcement details REGENXBIO’s planned presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, continuing a pattern of active investor engagement seen in prior conferences. Recent history featured pivotal trial enrollment completion and Q3 2025 results outlining cash of $302.0M and funding expectations into early 2027. The existing $300,000,000 S-3 shelf registration provides capital-raising flexibility, so monitoring future financing actions alongside clinical and regulatory milestones remains important.

Key Figures

Conference date: January 14, 2026 Presentation time: 10:30 a.m. PT Webcast replay period: 30 days

Conference date

January 14, 2026

J.P. Morgan Healthcare Conference presentation

Presentation time

10:30 a.m. PT

Scheduled J.P. Morgan conference slot

Webcast replay period

30 days

Archived replay availability after presentation

Historical Context

5 past events · Latest: Nov 25

5 events

1. Nov 25

   Investor conference

   24h Move

   +10.0%

   Announcement of participation in Piper Sandler healthcare conference with webcast access.

2. Nov 06

   Earnings update

   24h Move

   -3.8%

   Q3 2025 financials and timelines for RGX-202, RGX-121 and wet AMD programs.

3. Oct 30

   Clinical milestone

   24h Move

   -0.2%

   Completion of pivotal AFFINITY DUCHENNE enrollment and start of commercial production.

4. Oct 29

   Earnings call notice

   24h Move

   -2.4%

   Scheduling of Nov 6 call to discuss Q3 2025 financial results and operations.

5. Oct 15

   Investor conferences

   24h Move

   +9.3%

   Multiple announced conference appearances with webcast access for investors.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ROCKVILLE, Md., Dec. 18, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present at the 44^th Annual J.P. Morgan Healthcare Conference.

Presentation Details
Date and Time: Wednesday, January 14, 2026 at 10:30 a.m. PT
Location: Westin St. Francis, San Francisco, CA

A live webcast of the presentation can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.

Contacts:

Dana Cormack
Corporate Communications
dcormack@regenxbio.com 

Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-302645444.html

SOURCE REGENXBIO Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will REGENXBIO (RGNX) present at the J.P. Morgan Healthcare Conference?

REGENXBIO will present on January 14, 2026 at 10:30 a.m. PT.

Where is REGENXBIO (RGNX) presenting at the January 2026 J.P. Morgan conference?

The presentation is scheduled at the Westin St. Francis in San Francisco, CA.

How can investors watch the REGENXBIO (RGNX) presentation online?

A live webcast will be available in the Investors section of REGENXBIO's website.

Will a replay of the REGENXBIO (RGNX) webcast be available after the J.P. Morgan presentation?

Yes, an archived replay will be available for approximately 30 days following the presentation.

What time is 10:30 a.m. PT on January 14, 2026 in Eastern Time for REGENXBIO (RGNX) viewers?

10:30 a.m. PT on January 14, 2026 is 1:30 p.m. ET.